-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Private Advisor Group LLC Purchases 776 Shares of PerkinElmer, Inc. (NYSE:PKI)
Private Advisor Group LLC Purchases 776 Shares of PerkinElmer, Inc. (NYSE:PKI)
Private Advisor Group LLC lifted its position in PerkinElmer, Inc. (NYSE:PKI – Get Rating) by 23.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 4,156 shares of the medical research company's stock after purchasing an additional 776 shares during the quarter. Private Advisor Group LLC's holdings in PerkinElmer were worth $591,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in PKI. Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in PerkinElmer by 20.9% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,267 shares of the medical research company's stock worth $1,176,000 after acquiring an additional 1,430 shares during the last quarter. Wedmont Private Capital grew its holdings in PerkinElmer by 48.1% during the 2nd quarter. Wedmont Private Capital now owns 2,481 shares of the medical research company's stock worth $353,000 after acquiring an additional 806 shares during the last quarter. DnB Asset Management AS grew its holdings in PerkinElmer by 8.7% during the 2nd quarter. DnB Asset Management AS now owns 25,482 shares of the medical research company's stock worth $3,624,000 after acquiring an additional 2,033 shares during the last quarter. Moody National Bank Trust Division acquired a new position in PerkinElmer during the 2nd quarter valued at about $208,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in PerkinElmer by 14.3% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,704 shares of the medical research company's stock valued at $5,008,000 after purchasing an additional 3,595 shares during the period. Institutional investors own 77.06% of the company's stock.
Get PerkinElmer alerts:Insider Transactions at PerkinElmer
In other news, insider Daniel R. Tereau sold 5,700 shares of the firm's stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $145.14, for a total transaction of $827,298.00. Following the completion of the transaction, the insider now directly owns 13,380 shares of the company's stock, valued at approximately $1,941,973.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Daniel R. Tereau sold 5,700 shares of the firm's stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $145.14, for a total transaction of $827,298.00. Following the completion of the transaction, the insider now directly owns 13,380 shares of the company's stock, valued at approximately $1,941,973.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Andrew Okun sold 3,173 shares of the firm's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $165.42, for a total transaction of $524,877.66. Following the completion of the transaction, the insider now directly owns 6,391 shares of the company's stock, valued at $1,057,199.22. The disclosure for this sale can be found here. Company insiders own 0.52% of the company's stock.
PerkinElmer Stock Performance
Shares of PKI stock opened at $131.35 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 2.02. The company has a market capitalization of $16.58 billion, a P/E ratio of 24.60, a price-to-earnings-growth ratio of 0.34 and a beta of 1.15. The company's 50 day moving average price is $139.53 and its two-hundred day moving average price is $147.12. PerkinElmer, Inc. has a 52 week low of $116.18 and a 52 week high of $203.16.PerkinElmer (NYSE:PKI – Get Rating) last announced its earnings results on Monday, August 1st. The medical research company reported $2.32 EPS for the quarter, topping the consensus estimate of $2.03 by $0.29. The firm had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.20 billion. PerkinElmer had a net margin of 13.21% and a return on equity of 16.68%. The business's quarterly revenue was up .1% on a year-over-year basis. During the same period last year, the company posted $2.83 EPS. On average, analysts expect that PerkinElmer, Inc. will post 7.83 earnings per share for the current fiscal year.
PerkinElmer Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, November 11th. Stockholders of record on Friday, October 21st will be paid a dividend of $0.07 per share. The ex-dividend date is Thursday, October 20th. This represents a $0.28 annualized dividend and a dividend yield of 0.21%. PerkinElmer's dividend payout ratio is currently 5.24%.
Wall Street Analysts Forecast Growth
PKI has been the topic of a number of research reports. Stifel Nicolaus downgraded shares of PerkinElmer from a "buy" rating to a "hold" rating and cut their target price for the company from $190.00 to $170.00 in a research report on Thursday, August 18th. Robert W. Baird upped their target price on shares of PerkinElmer from $198.00 to $202.00 and gave the company an "outperform" rating in a research report on Tuesday, August 2nd. The Goldman Sachs Group cut their target price on shares of PerkinElmer from $200.00 to $175.00 and set a "neutral" rating on the stock in a research report on Thursday, July 14th. Barclays cut their price target on shares of PerkinElmer from $149.00 to $140.00 and set an "underweight" rating on the stock in a research report on Monday, September 12th. Finally, TheStreet downgraded shares of PerkinElmer from a "b" rating to a "c+" rating in a research report on Friday, September 23rd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, PerkinElmer has a consensus rating of "Hold" and a consensus price target of $162.50.
PerkinElmer Profile
(Get Rating)
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
Featured Stories
- Get a free copy of the StockNews.com research report on PerkinElmer (PKI)
- 3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
- Don't Forget About These Cheap, Fundamentally Strong Tech Stocks
- Bellwether RPM International Pops On Results
- Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
- Hot Potato: Lamb Weston Stock Confirms a Top
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.
根據最近提交給美國證券交易委員會的檔案,Private Advisor Group LLC在第二季度將其在PerkinElmer,Inc.(紐約證券交易所代碼:PKI-GET)的持倉上調了23.0%。該基金在本季度額外購買了776股後,持有這家醫學研究公司的4,156股股票。在最近一次報告期結束時,Private Advisor Group LLC持有的PerkinElmer股份價值591,000美元。
其他幾家大型投資者也改變了他們在PKI中的頭寸。三井住友DS資產管理有限公司第二季度增持PerkinElmer股份20.9%。三井住友DS資產管理有限公司在上個季度增持了1,430股後,現在擁有這家醫療研究公司8,267股股票,價值1,176,000美元。韋德蒙私人資本在第二季度增持了48.1%的PerkinElmer股份。韋德蒙私人資本公司現在擁有這家醫學研究公司2481股股票,價值35.3萬美元,在上個季度又購買了806股。DNB Asset Management AS在第二季度增持了8.7%的PerkinElmer股份。DNB Asset Management AS現在擁有這家醫療研究公司25,482股股票,價值3,624,000美元,此前在上個季度又購買了2,033股。穆迪國家銀行信託部門在第二季度收購了PerkinElmer的一個新頭寸,價值約20.8萬美元。最後,未來資產全球投資有限公司在第一季度將其在PerkinElmer的頭寸提高了14.3%。未來資產全球投資有限公司現在擁有28,704股這家醫療研究公司的股票,價值5,008,000美元,在此期間又購買了3,595股。機構投資者持有該公司77.06%的股份。
到達PerkinElmer警報:PerkinElmer的內幕交易
在其他新聞方面,內部人士Daniel·R·特羅在7月22日星期五的一筆交易中出售了5,700股該公司的股票。這些股票以145.14美元的平均價格出售,總成交金額為827,298.00美元。交易完成後,這位內部人士現在直接持有該公司13,380股股票,價值約1,941,973.20美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的,該檔案可通過此超鏈接。在其他新聞方面,內部人士Daniel·R·特羅在7月22日星期五的一筆交易中出售了5,700股該公司的股票。這些股票以145.14美元的平均價格出售,總成交金額為827,298.00美元。交易完成後,這位內部人士現在直接持有該公司13,380股股票,價值約1,941,973.20美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的,該檔案可通過此超鏈接。此外,內部人士安德魯·奧肯在8月1日星期一的一次交易中出售了3173股該公司的股票。這些股票以165.42美元的平均價格出售,總成交金額為524,877.66美元。交易完成後,該內部人士現在直接持有該公司6,391股股票,價值1,057,199.22美元。關於這次銷售的披露可以找到這裡。公司內部人士持有該公司0.52%的股份。
PerkinElmer股票表現
週四,PKI股票開盤報131.35美元。該公司的負債權益比率為0.63,速動比率為1.42,流動比率為2.02。該公司市值為165.8億美元,本益比為24.60倍,本益比為0.34倍,貝塔係數為1.15。該公司的50日移動均線價格為139.53美元,200日移動均線價格為147.12美元。PerkinElmer,Inc.的52周低點為116.18美元,52周高位為203.16美元。PerkinElmer(紐約證券交易所代碼:PKI-GET Rating)上一次公佈收益結果是在8月1日星期一。這家醫療研究公司公佈本季度每股收益為2.32美元,比普遍預期的2.03美元高出0.29美元。該公司本季度營收為12.3億美元,而市場普遍預期為12.億美元。PerkinElmer的淨利潤率為13.21%,股本回報率為16.68%。該業務的季度收入同比增長了1.1%。去年同期,該公司公佈的每股收益為2.83美元。分析師平均預計,PerkinElmer,Inc.本財年每股收益將達到7.83美元。
PerkinElmer宣佈派息
該公司最近還宣佈了季度股息,將於11月11日星期五支付。10月21日(星期五)登記在冊的股東將獲得每股0.07美元的股息。除息日期為10月20日星期四。這意味著年化股息為0.28美元,股息收益率為0.21%。PerkinElmer的派息比率目前為5.24%。
華爾街分析師預測經濟增長
公鑰基礎設施已經成為許多研究報告的主題。Stifel Nicolaus在8月18日週四的一份研究報告中將PerkinElmer的股票評級從買入下調至持有,並將該公司的目標價從190.00美元下調至170.00美元。8月2日,羅伯特·W·貝爾德在一份研究報告中將PerkinElmer的股票目標價從198.00美元上調至202.00美元,並給予該公司“跑贏大盤”的評級。7月14日,高盛夫婦在一份研究報告中將PerkinElmer的股票目標價從200.00美元下調至175.00美元,並將其股票評級定為“中性”。巴克萊將PerkinElmer的股票目標價從149.00美元下調至140.00美元,並在9月12日週一的一份研究報告中將該股的評級定為“減持”。最後,華爾街在9月23日星期五的一份研究報告中將PerkinElmer的股票評級從“b”下調至“c+”。一名股票研究分析師將該股評級為賣出,5名分析師給予持有評級,4名分析師對該股給予買入評級。根據MarketBeat.com的數據,PerkinElmer的共識評級為持有,共識目標價為162.50美元。
PerkinElmer配置檔案
(獲取評級)
PerkinElmer,Inc.為全球診斷、生命科學和應用服務市場提供產品、服務和解決方案。它通過兩個部門運行:發現和分析解決方案以及診斷。發現與分析解決方案部門提供一整套解決方案,包括試劑、資訊學、檢測和成像技術,使科學家能夠加強生命科學研究市場的研究突破,以及合同研究和實驗室服務。
專題報道
- 免費獲取StockNews.com關於PerkinElmer的研究報告(PKI)
- 隨著治療競賽升溫,3只阿爾茨海默病股票將被買入
- 不要忘記這些廉價的、從根本上強勁的科技股
- 領頭羊RPM國際流行業績
- Rivian打掉了包袱,但仍有很多事情要做
- 辣洋芋:韋斯頓羊肉庫存漲幅居前
接受PerkinElmer Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對PerkinElmer和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧